Is Chromadex Corp. overvalued or undervalued?

As of 17 October 2025, the valuation grade for Chromadex Corp. has moved from expensive to attractive, indicating a shift in perception towards the stock's value. The company appears to be undervalued, particularly given its impressive PEG ratio of 0.07, which suggests significant growth potential relative to its price, alongside a high ROCE of 1532.90% and a ROE of 29.28%.
In comparison to peers, Chromadex Corp. has a P/E ratio of 63, which is notably higher than LifeVantage Corp.'s attractive P/E of 14.81, yet lower than USANA Health Sciences' expensive P/E of 16.23. Despite recent short-term underperformance, with a 1-month return of -23.88% compared to the S&P 500's 0.96%, the company has shown remarkable long-term performance, with a 1-year return of 113.08% versus the S&P 500's 14.08%. This long-term outperformance reinforces the attractiveness of Chromadex Corp.'s current valuation.